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A Phase II Trial of Carboplatin and Gemcitabine with
Exisulind (IND #65,056) in Patients with Advanced
Non-small Cell Lung Cancer: An Eastern Cooperative
Oncology Group Study (E1501)
Gregory A. Masters, MD,* Sigui Li, MS,† Afshin Dowlati, MD,‡ Stefan Madajewicz, MD,§
Corey Langer, MD, Joan Schiller, MD,¶ and David Johnson, MD#
Background: Carboplatin and gemcitabine are one standard regi-
men for patients with advanced non-small cell lung cancer
(NSCLC). The oral proapoptotic agent exisulind is a cyclic
guanosine monophosphate phosphodiesterase that increases apopto-
sis in vitro. We performed a phase II trial of carboplatin and
gemcitabine with exisulind in patients with advanced NSCLC.
Methods: Gemcitabine (1000 mg/m2 days 1 and 8) and carboplatin
(AUC  5 day 1) were administered every 21 days, with exisulind
orally at 250 mg orally twice daily continuously, starting day 1. The
primary objective was to evaluate the 18-month survival. Secondary
objectives included response rate, progression-free survival, and
toxicities. Eligibility included stage IIIB (pleural effusion) or stage
IV NSCLC, no previous chemotherapy, and an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) of 0-1.
Results: Of 57 eligible patients treated, 34 patients were male and
23 female, 42 had stage IV, six stage IIIB, and nine had recurrent
disease. The median age was 63 years (range, 37–83). Twenty-six
patients had an ECOG PS of 0 and 31 had a PS of 1. The majority
of grade 3–4 toxicities were hematologic. Grade 3–4 nonhemato-
logic toxicity seen in 5% of patients included nausea/vomiting in
16% and fatigue in 23% of patients. The overall response rate was
19.3%. Median progression-free survival was 4.7 months. Median
overall survival was 9.0 months. Eighteen-month overall survival
was 30%.
Conclusion: The chemotherapy combination of gemcitabine and
carboplatin with the oral proapoptotic agent exisulind is generally
well tolerated with principally hematologic toxicity. The statistical
endpoint of 17 patients alive at 18 months was met, but given
ongoing developments in advanced NSCLC, ECOG will not be
pursuing additional trials of exisulind in NSCLC.
Key Words: Non-small cell lung cancer, Phase II trial, Gemcitab-
ine, Carboplatin, Novel agent, Exisulind.
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Lung cancer is the leading cause of cancer-related death inthe United States. In the United States alone, there are
171,500 new cases and 156,100 deaths from lung cancer each
year.1 Non-small cell histology accounts for approximately
80% of all lung cancer cases.2 The majority of patients
present with locally advanced or metastatic disease, such that
curative treatment is not possible. Median survival for these
patients is poor. Chemotherapy has been shown to palliate
symptoms, improve quality of life, and prolong survival in
patients with incurable non-small cell lung cancer (NSCLC).3
Platinum-containing combination chemotherapy is con-
sidered a standard of care for treating good performance
status patients with advanced NSCLC.4–6 No single chemo-
therapy regimen has been established as the most effective
option, and randomized trials show similar efficacy for many
of the commonly used two-drug regimens.7,8 Therefore, the
choice of chemotherapy in advanced NSCLC is based on
individual patient characteristics, expected treatment-related
toxicities, and familiarity of the treating physician.
The combination of gemcitabine and carboplatin in
NSCLC9–14 has shown response rates ranging from 21% to
50%, with median survival times of approximately 8 to 12
months.9–11 Carrato et al.10,12 evaluated two schedules of
gemcitabine and carboplatin in NSCLC, either as a 21-day
schedule with gemcitabine (1000 mg/m2) given on days 1 and
8 or a 28-day schedule with gemcitabine given on days 1, 8,
and 15, and carboplatin (AUC  5) on day 1 in both
schedules. In these trials, there was less hematologic toxicity
on the 21-day schedule, with similar efficacy. With the
28-day regimen, neutropenia and thrombocytopenia occurred
in the majority of patients, primarily on or near day 15 of
each cycle. Based on these results, and the principal investi-
gator’s experience in a randomized phase II trial of a 21-day
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regimen versus a 28-day regimen of carboplatin and gemcit-
abine supporting the use of the 21-day regimen,11 as well as
results of a trial in stage III NSCLC trial incorporating the
21-day schedule,13 we chose the 21-day regimen for this trial,
with carboplatin given on day 1 and gemcitabine given days
1 and 8.
Exisulind, a metabolite of the nonsteroidal anti-inflam-
matory drug sulindac, is the first of a new class of selective
apoptotic antineoplastic drugs15 that induces apoptosis by
inhibiting the enzyme cyclic guanosine monophosphate phos-
phodiesterase, independent of cyclooxygenase (COX)-1 or
COX-2 inhibition.16 This oral proapoptotic agent may reduce
new colon polyp formation in patients with familial polyposis
and has been studied in combination with chemotherapy in
advanced NSCLC. A phase I trial through the University of
Wisconsin escalated exisulind from 125 mg twice daily to
250 mg twice daily orally on a daily basis in combination
with gemcitabine (at a dose of 1250 mg/m2 days 1 and 8
every 21 days).17 The dose of 250 mg orally twice daily was
well tolerated, with one of six patients developing dose-
limiting constipation. No additional grade 3–4 toxicities were
observed at this dose level. Therefore, the combination of
gemcitabine and carboplatin with exisulind (given at 250 mg
orally twice daily) was expected to be well tolerated with no
unusual drug interactions or toxicities.
PATIENTS AND METHODS
Objectives
The primary objective of this phase II trial was to
examine the percentage of advanced NSCLC patients surviv-
ing 18 months when treated with carboplatin and gemcitabine
with exisulind. Secondary objectives included an evaluation
of the response rate, progression-free survival (PFS), and
overall median survival, as well as a description of the
feasibility and the toxicities of this regimen in patients with
advanced NSCLC.
Patient Eligibility
This multicenter phase II trial included patients with
pathologically confirmed stage IIIB (with pleural effusion) or
IV NSCLC who were 18 years of age and older and chemo-
therapy naı¨ve and had measurable or nonmeasurable (assess-
able) disease by Response Evaluation Criteria in Solid Tu-
mors (RECIST) criteria. Patients were required to have
adequate hematologic (white blood cells 3000/mm3, gran-
ulocytes 1500/mm3, platelets 100,000/mm3, hemoglobin
9 g/liter) hepatic (serum bilirubin 1.25 x institutional
upper normal limit and aspartamine transferase 1.5 x insti-
tutional upper normal limit), and renal (serum creatinine 2
mg/dl or calculated creatinine clearance 50 ml/min) func-
tion and an Eastern Cooperative Oncology Group (ECOG)
performance status of 0-1. No previous radiation to the site to
be followed for response was allowed, and any previous
radiation therapy had to be completed 3 weeks before
enrollment. Previously treated and controlled brain metasta-
ses were allowed. Patients with active hepatobiliary disease
were advised of potentially increased risks by the treating
physician. Concurrent aspirin, COX-2 inhibitors, or nonste-
roidal anti-inflammatory drugs, with the exception of low-
dose aspirin, ibuprofen, or naproxen, was not allowed. All
patients were required to give written informed consent and
were counseled on use of an approved method of contracep-
tion if of childbearing potential. The institutional review
board of each participating center reviewed and approved this
study.
Treatment Plan
Patients received gemcitabine 1000 mg/m2 as a 30-
minute intravenous infusion on days 1 and 8 followed by
carboplatin at a dose of AUC  5 administered over 30
minutes as an intravenous infusion on day 1 only of the
21-day cycle. Exisulind was given as an oral drug at 250 mg
twice daily starting on day 1 of chemotherapy and continued
until progressive disease or undue toxicity. The chemother-
apy cycle was repeated every 21 days until disease progres-
sion, intolerable toxicity, or for a maximum of six cycles.
No other chemotherapy, immunotherapy, antitumor
hormonal therapy (excluding contraceptives and replacement
steroids), radiation therapy, or experimental medications
were permitted while the patients were on the treatment
protocol.
For dose modifications, platelets, granulocytes, and
nonhematologic toxicities were clinically evaluated on day 8.
If granulocytes were between 500 and 1000/mm3 or platelets
were between 50,000 and 75,000/mm3, doses were to be
reduced by 25%. If granulocytes were500/mm3 or platelets
were 50,000/mm3, treatment was to be withheld. After
grade 3 or 4 nonhematologic events, treatment was withheld
until toxicities resolved to grade 2 or lower. For subsequent
treatment cycles, day 1 chemotherapy resumed provided the
following criteria were met: neutrophils 1000/mm3, plate-
lets 100,000/mm3, and all nonhematologic toxicities had
resolved to grade 2 or lower.
Response Criteria
Tumor response assessments were based on modified
RECISTriteria.18 Complete response was defined as the dis-
appearance of all known disease (target and nontarget le-
sions) determined by two observations not less than 4 weeks
apart. A partial response was defined as a 30% reduction from
baseline in the sum of the longest diameter (LD) of the target
lesions taking as reference the baseline LD sum and a lack of
disease progression in nontarget lesions. Progressive disease
was defined as the development of any new lesions or an
increase of 20% in the LD sum of target lesions taking as
reference the smallest sum LD recorded since the treatment
started. Patients were recorded as having stable disease if
they did not meet the criteria for response or progressive
disease.
Overall survival time was defined as the time from the
date of study entry to the date of death from any cause.
Survival time was censored at the date of the last follow-up
visit for patients who were still alive. PFS was defined as the
time from the date of registration to the first date of docu-
mented progression or death from any cause.
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Statistical Design and Analysis
All patients were followed for a minimum of 18
months. The proportion of patients surviving 18 months after
registration to this trial was the primary endpoint. In the
original design, the null survival proportion at 18 months was
expected to be 21% (median overall survival of 8 months
based on E1594). Alternatively, the treatment would be
considered effective if the true survival proportion at 18
months was 38% or higher (median overall survival of 12.9
months). We chose this endpoint over response rate alone
because the addition of a proapoptotic agent might not add to
tumor shrinkage, but might delay progressive cancer and
prolong survival. In choosing the 18-month survival end-
point, we could design a trial of reasonable size to determine
the potential benefit of this new drug. Fifty-seven eligible
patients were enrolled to this study. Based on the original
design, this treatment could be considered for further inves-
tigation if at least 17 of the 57 eligible patients were alive at
18 months using a one-sided   0.1 level exact test with
90% power.
Secondary endpoints of this study were PFS, objective
response rate and toxicity. Overall survival was defined as
time from date of study entry to death or last contact alive.
PFS was defined as time from date of study entry to tumor
progression or death without documented disease progression
or date last known alive without progression. Overall survival
and PFS curves were constructed using the Kaplan-Meier
method.19 Adverse events were assessed using National Can-
cer Institute Common Toxicity Criteria version 2.0.
RESULTS
A total of 59 patients were registered onto this coop-
erative group study from 17 institutions. The trial was acti-
vated on August 7, 2002. Full accrual was reached, and as a
result, the study was terminated on February 28, 2003. Of the
patients enrolled, one patient was ineligible due to the timing
of radiation (per protocol, patients must have completed any
radiation therapy 3 weeks before registration). One addi-
tional patient was eligible but never started assigned therapy
due to progression before the start of treatment. The afore-
mentioned two cases were excluded from analyses.
Patient Characteristics
Table 1 shows the baseline characteristics of the 57
eligible and treated patients. A majority of the patients were
white (91%) and had nonrecurrent stage IV disease (74%).
The proportion of males was 60% compared to 40% female.
From 6 months before entry, approximately 76% of patients
had a weight loss of less than 5%. The median age was 63
years old (range, 37–83). Less than half of the patients had
previous surgery (26%) and previous radiation therapy
(23%). Fifty-four percent of patients had an ECOG perfor-
mance status of 1. Fifty-two percent had a histologic diagno-
sis of adenocarcinoma.
Treatment
As per protocol, patients received gemcitabine and
carboplatin until disease progression or a maximum of six
cycles. Exisulind was given indefinitely unless patient with-
drew consent, had disease progression or unacceptable tox-
icity, or at the attending physician’s discretion. Of 57 eligible
and treated patients, 25 (44%) patients received a total of six
cycles of gemcitabine and carboplatin with exisulind, of
whom 17 patients received additional cycles of exisulind. The
median number cycles of the three-drug combination com-
TABLE 1. Baseline Patient Characteristics
Characteristic
Total (n  57)
N %
Sex
Male 34 60
Female 23 40
Age, y, median (range) 63 (37–83)
Race
White 52 91
Black 5 9
Weight loss in previous 6 mo
5% of body weight 43 76
5% to 10% of body weight 4 7
10% to 20% of body weight 7 12
20% of body weight 3 5
Stage
IIIB (not recurrent) 6 11
IV (not recurrent) 42 74
Recurrent 9 16
Performance status
0 26 46
1 31 54
Histology
Squamous 10 18
Adenoscarcinoma 24 42
Large cell undifferentiated 3 5
Bronchoalveolar 1 2
Non-small cell NOS 16 288
Other 3 5
Sites of metastatic disease
Hilar nodes 32 56
Mediastinal nodes 34 60
Supraclavicular scalene nodes 5 9
Ipsilateral lung 27 47
Contralateral lung 14 25
Pleura 17 30
Liver 7 12
Adrenal 10 18
Bone 13 23
Brain 10 18
Other 14 25
Previous surgery
Yes 15 26
No 42 74
Previous radiation therapy
Yes 13 23
No 44 77
NOS, not otherwise specified.
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pleted was four (range, one to six) for all patients. Among 11
responders, two patients had five cycles of chemotherapy and
one patient had six cycles of chemotherapy. Eight patients
had more than six cycles of exisulind in addition to the six
cycles of three-drug therapy. Among 46 nonresponders, 30
patients had fewer than six cycles of chemotherapy, seven
had six cycles of treatment, and nine had extra cycles of
exisulind in addition to six cycles of chemotherapy.
Tumor Response
Table 2 gives a summary of the best objective response
including reasons for cases that were not assessable for
response. Of the 57 eligible patients, two (4%) patients had
complete response, nine (16%) patients achieved a partial
response, 31 (54%) experienced stable disease as best re-
sponse, 12 (21%) had progressive disease, and three (5%)
were not assessable for response. Reasons patients were not
assessable included patient noncompliance in coming in for a
follow-up scan1 and patients coming off study due to grade 4
toxicity.2 The overall objective response rate was 19.3%
(11/57) (90% exact binomial confidence interval [CI]:
11.2%–29.9%).
Overall Survival and PFS Analysis
Figure 1 displays the Kaplan-Meier estimate of the
distribution of overall survival. The 18-month overall sur-
vival rate was 29.8% (95% CI: 17.9%–41.7%), with 17 of 57
eligible patients alive at 18 months. The 1-year survival rate
was 42% and the 2-year overall survival rate was 11.3%. The
median overall survival was 9.0 months (95% CI: 6.3–13.5).
The Kaplan-Meier estimate of the distribution of PFS is
presented in Figure 2. The median PFS was 4.7 months (95%
CI: 3.4–5.6). The 1-year PFS rate was 10.5% (95% CI:
2.6%–18.6%). The 18-month PFS was 3.5% (95% CI: 0.0%–
8.3%).
Toxicity Summary
Toxicity data were evaluated by the National Cancer
Institute/Common Toxicity Criteria (version 2.0). Table 3
shows grade 3 to 4 treatment-related toxicities for the 57
patients who received therapy. Among the 57 treated patients
who received treatment, nine (15.7%) had a worst toxicity
grade of 1 or 2, 28 (49%) had a worst toxicity grade of 3, 21
(37%) had a worst toxicity grade of 4, and no grade 5 toxicity
was observed. The most common severe or life-threatening
(grade 3 or 4) toxicities were hematologic. Grade 4 leukope-
nia (2%), neutropenia (23%), anemia (5%), and thrombocy-
topenia (9%) were uncommon. Fatigue and nausea were the
only grade 3 to 4 nonhematologic toxicities observed in more
than 10% of patients. Grade 1 or greater alopecia was re-
ported in 20 of 58 patients (34%).
DISCUSSION
Current clinical data and American Society of Clinical
Oncology practice guidelines20 suggest that combination che-
motherapy, generally with a platinum analogue, is the stan-
dard of care for patients with advanced NSCLC. These
combinations produce response rates of 15% to 40% and
median overall survival times of 8 to 10 months in trials
involving predominantly stage IV patients. No single chemo-
therapy regimen has emerged as consistently superior in this
disease.
Recent studies using combination chemotherapy with
gemcitabine and carboplatin in NSCLC show similar re-
sponse rates in the range of 30% to 50% and median survival
times ranging from 6 to 16 months.9–14,21–25 For these trials,
the main dose-limiting toxicities are hematologic. The com-
bination is a reasonable standard on which to build.
Research investigating the incorporation of newer tar-
geted agents in advanced NSCLC has been frustrating. Al-
though several new agents have emerged with promising
TABLE 2. Response Summary
Total (n  57)
Response n %
Complete response 2 4
Partial response 9 16
Stable disease 31 54
Progressive disease 12 21
Unassessable 3 5
FIGURE 1. Overall survival in months.
FIGURE 2. Progression-free survival in months.
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preclinical data on tumor cell control, trials of combined
chemotherapy and targeted therapy given concurrently have
been disappointing.26,27 A recent trial, however, has shown a
survival benefit with the addition of the antiangiogenic agent
bevacizumab to combination chemotherapy with carboplatin
and paclitaxel.28 These data must be interpreted cautiously,
however, because they will apply to a minority of advanced
lung cancer patients given the toxicity profile and strict
eligibility criteria for this new targeted drug. Thus, the search
for new and more effective treatment strategies continues.
The regimen studied here of carboplatin and gemcitab-
ine with exisulind was generally well tolerated with accept-
able hematologic and nonhematologic toxicities. Exisulind
did not appear to exacerbate these toxicities. The rate of
neutropenic fever was low. The low rate of alopecia with this
carboplatin/gemcitabine/exisulind regimen was also encour-
aging because many patients would prefer to avoid this
toxicity.
This study was designed to assess the overall survival at
18 months associated with carboplatin and gemcitabine in
combination with exisulind among patients with advanced
NSCLC. Based on the 18-month overall survival of 21% in
ECOG E1594,7 we calculated that statistically it would be of
interest to detect an absolute improvement of 17% (i.e., to
38%) in 18-month overall survival in this study. This regimen
achieved an 18-month overall survival rate of 29.8% (95%
CI: 17.9%–41.7%), with 17 of 57 patients alive at 18 months.
Although this met the original statistical design endpoint, the
clinical relevance is diminished with the advent of newer
antiangiogenic agents such as bevacizumab, which have
shown a significant survival advantage in an ECOG phase III
trial.28
Many previous studies have employed the 21-day reg-
imen of gemcitabine plus carboplatin used in the current trial,
with most achieving response rates near 30% and median
survival near 9 months.23 Although the response rate ob-
served in this study was lower at 19%, median survival (9.0
months) and 1- and 2-year survival rates (42% and 11%,
respectively) are comparable to historical results with this and
other chemotherapeutic regimens.7 These data suggest a lack
of any major contribution of the additional of exisulind to
carboplatin and gemcitabine. It is possible that other sched-
ules of this combination might yield more favorable results,
such as sequential therapy rather than concurrent treatment.
Nonetheless, in the context of the significant survival benefit
observed with bevacizumab in ECOG E4599, our results do
not warrant additional investigation of this regimen.
We conclude that any clinical benefit observed when
exisulind is added to the gemcitabine and carboplatin regimen
in advanced NSCLC is marginal, and the regimen will not be
pursued further in the ECOG due to our desire to follow more
promising directions in clinical research, especially in the
field of angiogenesis inhibitors such as bevacizumab. Al-
though the toxicity of this regimen is reasonable, the search
for additional agents with single-agent activity and synergy
with current chemotherapy regimens must take precedence.
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